Reserach programme: systemic lupus erythematosus therapeutics - Diamante
Latest Information Update: 20 Mar 2026
At a glance
- Originator Diamante
- Class Immunotherapies; Peptides
- Mechanism of Action Cytokine modulators; Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Systemic lupus erythematosus
Most Recent Events
- 19 Mar 2026 Early research in Systemic lupus erythematosus in Italy (Parenteral), before March 2026 (Diamante Website, March 2026)